DOI QR코드

DOI QR Code

From Bench to Market: Preparing Human Pluripotent Stem Cells Derived Cardiomyocytes for Various Applications

  • Moon, Sung-Hwan (Department of Medicine, School of Medicine, Konkuk University) ;
  • Bae, Daekyeong (Mirae Cell Bio Inc.) ;
  • Jung, Taek-Hee (Department of Stem Cell Biology, School of Medicine, Konkuk University) ;
  • Chung, Eun-Bin (Department of Stem Cell Biology, School of Medicine, Konkuk University) ;
  • Jeong, Young-Hoon (Department of Stem Cell Biology, School of Medicine, Konkuk University) ;
  • Park, Soon-Jung (Department of Stem Cell Biology, School of Medicine, Konkuk University) ;
  • Chung, Hyung-Min (Department of Stem Cell Biology, School of Medicine, Konkuk University)
  • Accepted : 2017.04.27
  • Published : 2017.05.30

Abstract

Human cardiomyocytes (CMs) cease to proliferate and remain terminally differentiated thereafter, when humans reach the mid-20s. Thus, any damages sustained by myocardium tissue are irreversible, and they require medical interventions to regain functionality. To date, new surgical procedures and drugs have been developed, albeit with limited success, to treat various heart diseases including myocardial infarction. Hence, there is a pressing need to develop more effective treatment methods to address the increasing mortality rate of the heart diseases. Functional CMs are not only an important in vitro cellular tool to model various types of heart diseases for drug development, but they are also a promising therapeutic agent for cell therapy. However, the limited proliferative capacity entails difficulties in acquiring functional CMs in the scale that is required for pathological studies and cell therapy development. Stem cells, human pluripotent stem cells (hPSCs) in particular, have been considered as an unlimited cellular source for providing functional CMs for various applications. Notable progress has already been made: the first clinical trials of hPSCs derived CMs (hPSC-CMs) for treating myocardial infarction was approved in 2015, and their potential use in disease modeling and drug discovery is being fully explored. This concise review gives an account of current development of differentiation, purification and maturation techniques for hPSC-CMs, and their application in cell therapy development and pharmaceutical industries will be discussed with the latest experimental evidence.

Keywords

Acknowledgement

Supported by : National Research Foundation (NRF), Korea National Institute of Health

Cited by

  1. MicroRNA-29b-3p Targets SPARC Gene to Protect Cardiocytes against Autophagy and Apoptosis in Hypoxic-Induced H9c2 Cells vol.12, pp.4, 2019, https://doi.org/10.1007/s12265-018-9858-1
  2. SMYD2 Drives Mesendodermal Differentiation of Human Embryonic Stem Cells Through Mediating the Transcriptional Activation of Key Mesendodermal Genes vol.37, pp.11, 2017, https://doi.org/10.1002/stem.3068
  3. Cell Therapy With Human ESC-Derived Cardiac Cells: Clinical Perspectives vol.8, pp.None, 2017, https://doi.org/10.3389/fbioe.2020.601560